Japanese drugmaker Hisamitsu Pharmaceutical’s (TYO: 4530) has announced the results of a Phase II clinical study for a transdermal drug for the treatment of Parkinson’s disease in Japan
The efficacy and safety of the HP-3000 (ropinirole hydrochloride) were compared with a placebo in patients with Parkinson’s disease who concomitantly used L-dopa (levodopa). A statistically significant difference was confirmed for improvement in the primary efficacy endpoint compared with the placebo group.
The product is a transdermal formulation developed using Hisamitsu’s TDDS (Transdermal Drug Delivery System) technology. Hisamitsu aims to initiate a Phase III clinical study later this year.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze